Fenbendazole as a potential anticancer drug (taxane comparison) (2013)

Peer-Reviewed Study · Duan Q, Liu Y, Rockwell S · February 2013

Duan Q et al., 2013-02: The Yale study behind the 'works like a taxane' framing says only that fenbendazole's mechanisms of action overlap with the taxanes and with hypoxia-selective cytotoxins, and it found no antitumour effect in mice and only additive cytotoxicity with docetaxel.

To evaluate the anticancer activity of fenbendazole, a widely used antihelminth with mechanisms of action that overlap with those of the hypoxia-selective nitroheterocyclic cytotoxins/radiosensitizers and the taxanes.

Duan Q et al., 2013-02: The Yale study behind the 'works like a taxane' framing says only that fenbendazole's mechanisms of action overlap with the taxanes and with hypoxia-selective cytotoxins, and it found no antitumour effect in mice and only additive cytotoxicity with docetaxel. F4. What the paper actually says: fenbendazole is cytotoxic in culture, toxicity rises with time and hypoxia, it does not change the radiation or docetaxel dose-response curves (additive only), and it does not alter EMT6 tumour growth in mice. Mechanism contrast: paclitaxel stabilises microtubules (promotes assembly), whereas Dogra 2018 calls fenbendazole a 'moderate microtubule destabilizing agent' with micromolar affinity for mammalian tubulin – so 'works like paclitaxel' is wrong in mechanism and unsupported in effect. Study details in the C2 Duan row. Also filed as FBA-11, FBC-29, FBC-07 (claims C1, C2, C6, F4).